undamentalytics Newsletter
Sign in

Neuropace Inc (NPCE) stock

Add to watchlist

Add holding +

NASDAQ: NPCE Nasdaq Health Care Equipment Next results ~November 12, 2026

Neuropace Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Neuropace Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds65 adding, 54 cuttingOf 26 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Neuropace files

Where Neuropace stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $99m, up 16.9% on a year earlier, faster than the 13.3% growth a quarter earlier. Free-cash-flow margin rose to -11.7% from -19.4% a year earlier. Operating margin widened to -15.3% from -25.1%. The diluted share count is up 8.6% on a year earlier, which dilutes existing holders. It passes 2 of our 7 financial-health checks.

Our model value for Neuropace is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Neuropace Inc's trailing-twelve-month revenue grew 16.9% year on year, with a free-cash-flow margin of -11.7%.

Current signal Gross margin expanding: TTM gross margin reached 79.6%, up 2.6pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 16.9% over the last 12 months.
  • Growth speeding up. The growth rate is 3.6 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 9.9 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -15.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -11.7% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 8.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 62% and a beta of 1.4 against the S&P 500.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.18 against an average estimate of -$0.19: beat by 5.6%
Revenue
$23m, up 17.1% on a year earlier
Share reaction
-2.2% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.09

Neuropace's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.3%
  • 1 week-5.0%
  • 1 month-2.8%
  • This year-20.1%
  • 1 year+24.1%
  • 5 years-22.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$98.8M
Operating margin
-15.3%
Net margin
-19.3%
EPS (TTM, diluted)
$-0.57

Growth

Revenue growth
+16.9%
Change in growth rate
+3.6 pts
Share count change
+8.6%

Cash

Free cash flow (TTM)
-$11.6M
FCF margin
-11.7%
Stock pay % of revenue
9.9%

Earnings

Last results
August 11, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Neuropace Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$10.08$1.49$10.31$11.19$15.44$12.34
Market value$167m$37m$267m$326m$505m$415m
+ Net debt (− = net cash)$31m$46m$39m$46m$37m$46m
Enterprise value$198m$83m$305m$372m$542m$461m
Multiples
Price / sales 3.7x0.8x4.1x4.1x5.1x4.2x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

37 /100

Weak moat

How hard Neuropace's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -28.1% of total assets over 6 years.

  • Pricing power 19 / 20

    Gross margin has been a median 74.7%, moving by 2.7 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -30.6%; its worst year was -83.9%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -37.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $27m and EPS of −$0.09 (range −$0.15 to −$0.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.43 +34% $100m +0%
Next −$0.22 +50% $122m +22%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −20.3% on 90 days ago. In the last 30 days, 7 analysts raised Neuropace Inc's forecast and 0 cut it.

Consensus EPS forecast Neuropace Inc, last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.54 Current fiscal year, 60 days ago: −$0.45 Current fiscal year, 30 days ago: −$0.43 Current fiscal year, 7 days ago: −$0.43 Current fiscal year, Now: −$0.43 −$0.43 Next fiscal year, 90 days ago: −$0.29 Next fiscal year, 60 days ago: −$0.22 Next fiscal year, 30 days ago: −$0.22 Next fiscal year, 7 days ago: −$0.22 Next fiscal year, Now: −$0.22 −$0.22

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.54−$0.29
60 days ago −$0.45−$0.22
30 days ago −$0.43−$0.22
7 days ago −$0.43−$0.22
Now −$0.43−$0.22

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.19 −$0.18 +5.6%
Dec 2025 −$0.15 −$0.08 +48.1%
Sept 2025 −$0.19 −$0.11 +43.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

10 analysts, Oct 2026
Buy10100%
Hold00%
Sell00%

Monthly trend

  1. Oct 20261910
  2. Sep 20261910
  3. Aug 2026189
  4. Jul 2026189

Counts of recommendations published by analysts covering Neuropace Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.0%
of tradable shares
Days to cover
6.96
at average volume
Short interest, 1 month
−7%
to October 15, 2026
Held by institutions
97%
of shares
Held by insiders
4.5%
of shares
Employees
220
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +24.1%

$9.94 on October 31, 2025 to $12.34

ThenNowEffect
Revenue (last 12 months) $85m $99m +16.9%
P/S multiple 3.6x 4.2x +15.3%
Share count 31m 34m −7.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +72.1%

$7.17 on November 3, 2023 to $12.34

ThenNowEffect
Revenue (last 12 months) $55m $99m +79.9%
P/S multiple 3.3x 4.2x +28.3%
Share count 25m 34m −25.5%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
NPCE−85%+592%+9%+38%−20%
Industry peers (median)−37%−9%−20%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
NPCE17%67%58%42%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
NPCE−89%−39%−66%−55%−37%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 22, 2021: 95% from April 27, 2021 to December 28, 2022. Getting back needed a 1954% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$9.40 – $19.29
From 52-week high
−36.0%
vs 50-day average
−9.6%
vs 200-day average
−17.5%
Volatility (1 year)
63%
Beta vs S&P 500
1.39

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±11.7%
After a week
6 up, 6 down
typical move ±14.3%
After a month
7 up, 5 down
typical move ±20.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −2.2% −0.1% −2.8% −6.8%
May 12, 2026 +0.9% +0.4% +1.1% +1.1%
March 3, 2026 −1.4% −0.2% +0.5% −0.6%
November 4, 2025 +38.1% −0.8% +43.5% +80.5%
August 12, 2025 +4.8% +1.4% −7.2% +12.6%
May 13, 2025 +16.7% +0.8% +34.6% −16.0%
March 4, 2025 −1.5% −0.1% −12.3% +14.6%
January 28, 2025 +3.2% +0.4% −2.4% −11.8%
January 8, 2025 −3.9% −1.4% −4.1% +0.8%
November 12, 2024 +25.7% −0.3% +26.1% +49.9%
August 13, 2024 −1.9% +2.0% +4.9% +4.8%
May 8, 2024 −40.1% +0.6% −32.1% −51.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Neuropace Inc
$60M $70M $80M $90M $100M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $60.2M Revenue (TTM), FY23 Q4: $65.4M Revenue (TTM), FY24 Q1: $69.1M Revenue (TTM), FY24 Q2: $71.8M Revenue (TTM), FY24 Q3: $76.5M Revenue (TTM), FY24 Q4: $79.9M Revenue (TTM), FY25 Q1: $84.3M Revenue (TTM), FY25 Q2: $84.6M Revenue (TTM), FY25 Q3: $90.8M Revenue (TTM), FY25 Q4: $96M Revenue (TTM), FY26 Q1: $95.5M Revenue (TTM), FY26 Q2: $98.8M $98.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $60.2M
FY23 Q4 $65.4M
FY24 Q1 $69.1M
FY24 Q2 $71.8M
FY24 Q3 $76.5M
FY24 Q4 $79.9M
FY25 Q1 $84.3M
FY25 Q2 $84.6M
FY25 Q3 $90.8M
FY25 Q4 $96M
FY26 Q1 $95.5M
FY26 Q2 $98.8M
Revenue growth, TTM YoY Neuropace Inc
0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 37.7% Revenue growth, TTM YoY, FY23 Q4: 43.7% Revenue growth, TTM YoY, FY24 Q1: 42.1% Revenue growth, TTM YoY, FY24 Q2: 30.8% Revenue growth, TTM YoY, FY24 Q3: 27.0% Revenue growth, TTM YoY, FY24 Q4: 22.1% Revenue growth, TTM YoY, FY25 Q1: 22.1% Revenue growth, TTM YoY, FY25 Q2: 17.7% Revenue growth, TTM YoY, FY25 Q3: 18.8% Revenue growth, TTM YoY, FY25 Q4: 20.1% Revenue growth, TTM YoY, FY26 Q1: 13.3% Revenue growth, TTM YoY, FY26 Q2: 16.9% 16.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 37.7%
FY23 Q4 43.7%
FY24 Q1 42.1%
FY24 Q2 30.8%
FY24 Q3 27.0%
FY24 Q4 22.1%
FY25 Q1 22.1%
FY25 Q2 17.7%
FY25 Q3 18.8%
FY25 Q4 20.1%
FY26 Q1 13.3%
FY26 Q2 16.9%
Operating margin (TTM) Neuropace Inc
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -53.1% Operating margin (TTM), FY23 Q4: -41.5% Operating margin (TTM), FY24 Q1: -38.2% Operating margin (TTM), FY24 Q2: -34.5% Operating margin (TTM), FY24 Q3: -30.2% Operating margin (TTM), FY24 Q4: -27.1% Operating margin (TTM), FY25 Q1: -22.9% Operating margin (TTM), FY25 Q2: -25.1% Operating margin (TTM), FY25 Q3: -21.6% Operating margin (TTM), FY25 Q4: -18.4% Operating margin (TTM), FY26 Q1: -19.0% Operating margin (TTM), FY26 Q2: -15.3% -15.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -53.1%
FY23 Q4 -41.5%
FY24 Q1 -38.2%
FY24 Q2 -34.5%
FY24 Q3 -30.2%
FY24 Q4 -27.1%
FY25 Q1 -22.9%
FY25 Q2 -25.1%
FY25 Q3 -21.6%
FY25 Q4 -18.4%
FY26 Q1 -19.0%
FY26 Q2 -15.3%
FCF margin (TTM) Neuropace Inc
-60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -40.6% FCF margin (TTM), FY23 Q4: -30.4% FCF margin (TTM), FY24 Q1: -25.6% FCF margin (TTM), FY24 Q2: -24.1% FCF margin (TTM), FY24 Q3: -22.0% FCF margin (TTM), FY24 Q4: -22.8% FCF margin (TTM), FY25 Q1: -21.5% FCF margin (TTM), FY25 Q2: -19.4% FCF margin (TTM), FY25 Q3: -18.3% FCF margin (TTM), FY25 Q4: -11.8% FCF margin (TTM), FY26 Q1: -10.3% FCF margin (TTM), FY26 Q2: -11.7% -11.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -40.6%
FY23 Q4 -30.4%
FY24 Q1 -25.6%
FY24 Q2 -24.1%
FY24 Q3 -22.0%
FY24 Q4 -22.8%
FY25 Q1 -21.5%
FY25 Q2 -19.4%
FY25 Q3 -18.3%
FY25 Q4 -11.8%
FY26 Q1 -10.3%
FY26 Q2 -11.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 41 45 46 65 80 100 99
Gross profit 30 33 32 48 59 77 79
EBITDA −13 −23 −41 −27 −21 −16 −15
Operating income −13 −24 −41 −27 −22 −16 −15
Net income −24 −36 −47 −33 −27 −21 −19
Diluted EPS −$117.85 −$2.17 −$1.91 −$1.27 −$0.93 −$0.66 −$0.57
Growth (year on year)
Revenue — +9.8% +0.7% +43.7% +22.1% +25.1% +16.9%
Margins
Gross margin 73.6% 74.0% 71.4% 73.6% 73.9% 77.2% 79.6%
EBITDA margin −31.0% −51.9% −89.0% −41.3% −26.9% −16.1% −14.9%
Operating margin −31.7% −52.5% −89.6% −41.5% −27.1% −16.3% −15.3%
Net margin −59.0% −79.9% −103.4% −50.4% −34.0% −21.5% −19.3%
Free-cash-flow margin −52.7% −55.2% −82.3% −30.4% −22.8% −11.3% −11.7%
Cash flow
Cash from operations −22 −25 −37 −20 −18 −11 −11
Capital spending 0 0 1 0 0 0 0
Free cash flow −22 −25 −37 −20 −18 −11 −12
Stock-based pay 1 4 8 10 10 11 10
Free cash flow after stock pay −23 −29 −46 −29 −29 −22 −21
Balance sheet
Cash 26 19 7 18 13 22 13
Total debt 53 50 53 57 60 59 59
Net debt (negative = net cash) 26 31 46 39 46 37 46
Diluted shares — 17m 25m 26m 29m 33m 34m
Returned to shareholders
Buybacks — — — — 0 50 0
Total returned — — — — 0 50 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $97m
Short-term assets $86mLonger-term assets $11m
What it owes, and who funded it · $97m
Short-term liabilities $17mLonger-term liabilities $68mShareholders' equity $12m
  • Short-term assets cover short-term liabilities $86m of assets due within a year against $17m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $86m short-term assets against $68m of longer-dated liabilities.
  • More cash than debt $13m of cash against $59m of debt.
  • Debt below 40% of shareholders' equity Debt is 497% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 68% to 497% over five years.
  • A year's operating cash flow covers at least 20% of debt −$11m of operating cash flow against $59m of debt.
  • Operating profit covers interest at least five times over Operating income of −$15m against $6m of interest.

From Neuropace Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Diluted share count
+8.6%
year over year
Total shareholder yield
0.0%
dividends 0.0% + buybacks 0.0% of market value
R&D spending
28.0%
of revenue
Sales & admin spending
67.7%
of revenue
Days sales outstanding
55 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated NPCE CBLL DCTH IRMD XTNT SMTI Median
Revenue, last 12 months $99m $102m $95m $89m $110m $110m $99m
Revenue growth, last 12 months 16.9% 31.7% 35.8% 11.0% −14.3% 13.0% 9.3%
Revenue growth, 3-year average 21.6% — 230.8% 12.4% 17.3% 22.6% 14.0%
Revenue growth, latest quarter 17.1% 32.5% 20.6% 14.2% −35.0% 9.0% 10.5%
Gross margin 79.6% 88.9% 87.1% 75.5% 59.4% 93.0% 61.3%
Operating margin −15.3% −68.6% −1.9% 32.3% −9.6% 7.7% −8.7%
Operating margin, 3-year average −25.0% −65.1% −99.4% 31.0% −7.3% 2.2% −17.9%
Net margin −19.3% −64.7% 0.6% 26.8% −10.2% −29.2% −12.1%
Cash from operations / revenue −11.4% −53.0% 20.5% 30.4% 0.5% 5.2% −2.1%
Free-cash-flow margin −11.7% −53.7% 18.3% 29.3% −0.6% 4.1% −4.0%
Free-cash-flow margin, 3-year average −18.4% — −80.5% 24.2% −6.2% −0.1% −7.7%
Stock pay / revenue 9.9% 16.1% 21.2% 3.3% 2.7% 4.5% 6.3%
Change in share count 8.6% — 10.8% 0.3% 4.0% 0.3% 4.0%

Median of all 135 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$422M
Institutions reporting
113
Shares held vs prior quarter
▲ 0.5%
Positions opened / closed
17 / 18

Top buyers and sellers, Q2 2026: 65 institutions bought and 54 sold ; the biggest buyer was First Light Asset Management, LLC (+401K shares) and the biggest seller Orbimed Advisors LLC (−591K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Polar Capital Holdings PLC $52.4M 3.3M 12.4% 0.0%
Soleus Capital Management, L.P. $46.3M 2.9M 11.0% ▼ 0.7%
First Light Asset Management, LLC $45.5M 2.9M 10.8% ▲ 16.3%
Morgan Stanley $42.2M 2.7M 10.0% ▲ 3.4%
Blackrock, Inc. $39.4M 2.5M 9.3% ▲ 5.6%
Orbimed Advisors LLC $23.9M 1.5M 5.7% ▼ 28.2%
Driehaus Capital Management LLC $23M 1.4M 5.4% ▼ 0.3%
Vanguard Capital Management LLC $19.5M 1.2M 4.6% ▲ 9.2%
Deutsche Bank Ag\ $14.9M 939K 3.5% ▲ 0.7%
Armistice Capital, LLC $11M 692K 2.6% 0.0%
Geode Capital Management, LLC $10.6M 666K 2.5% ▲ 7.8%
FMR LLC $8.8M 555K 2.1% ▲ 0.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Neuropace Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $399,250 1 trade by 1 insider · 100% under pre-set plans
Net ▼ $399,250 net selling
Insider Date Trade Shares Price Value
Morrell Martha CHIEF MEDICAL OFFICER December 15, 2025 Sell pre-set plan 25,000 $15.97 $399,250

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 3, 2026
  • November 4, 2025
  • August 12, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Neuropace Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Neuropace Inc in brief

What does Neuropace Inc do?
Neuropace Inc is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Neuropace Inc's stock ticker?
Neuropace Inc trades under the ticker NPCE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Neuropace Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Neuropace Inc reported revenue of $98.8M, 16.9% higher than a year earlier, according to its SEC filings.
What is Neuropace Inc's free cash flow?
Neuropace Inc's free-cash-flow margin is -11.7% of revenue over the trailing twelve months.
Who are Neuropace Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Polar Capital Holdings PLC, Soleus Capital Management, L.P. and First Light Asset Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Neuropace Inc buying back stock, and does it pay a dividend?
Neuropace Inc spent $0 on share repurchases over the trailing twelve months, and its diluted share count still rose 8.6% over the year.
What is Neuropace Inc's market cap?
On November 2, 2026, Neuropace Inc's market capitalisation was about $415M and net debt of $46.5M. Market figures come from third-party market data and may be delayed.
How much debt does Neuropace Inc have?
Neuropace Inc's debt-to-equity ratio is 496.6%, from its latest balance sheet (67.8% five years earlier). The financial health section below sets out its other solvency checks.
Who are Neuropace Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Neuropace Inc are Ceribell, Inc., Delcath Systems, Inc., Iradimed Corp, Xtant Medical Holdings, Inc. and Sanara Medtech Inc. The side-by-side comparison below sets their revenue, margins and growth against Neuropace Inc's.
Are insiders buying or selling Neuropace Inc stock?
Over the last 12 months, Neuropace Inc's directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Neuropace Inc's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Neuropace Inc announces its own schedule.